Gastroenterology/Bariatrics Clinical Trial - Abbvie - M16-006

Status:

Open (Study open and enrolling)

ClinicalTrials.gov:

NCT03105128

The purpose of this study is to evaluate the efficacy and safety of risankizumab versus placebo during induction therapy in subjects with moderately to severely active Crohn's disease (CD).

Drug

Drug: Risankizumab IV, Risankizumab SC, Placebo for IV

Trial Type

Interventional

Age Range

18 years or older

Condition

Weight loss Crohn's Disease

Keywords

Crohn's Disease | M16-006 | Abbvie